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Introduction 
Human pharmaceuticals are produced in 
significant amounts with high production 
volume. Not surprisingly, pharmaceuticals have 
been detected around the world in a wide 
range of environmental media, such as urban 
and hospital wastewater effluents, surface 
waters, ground waters and drinking waters 
(e.g., Fatta-Kassinos et al., 2011). 
Consequently, the discharge of 
pharmaceuticals in wastewater into the aquatic 
environment has been a source of discussion 
and concern in scientific and regulatory circles 
for more than a decade (Daughton & Ternes, 
1999; Halling-Sørensen et al., 1998). The 
control of what are called hazardous 
substances in Europe falls under the Water 
Framework Directive (WFD). When an 
environmental quality standard (EQS) is set for 
a chemical this can lead to it being phased out 
of production. However, the recent addition of 
the pharmaceuticals 17α-ethinylestradiol 
(EE2), 17β-estradiol (E2) and diclofenac in the 
European Community document 
(COM(2011)876) appear to usher in a new era. 
The document suggested annual average EQS 
of 0.035 ng/L for EE2, 0.4 ng/L for E2 and 100 
ng/L for diclofenac.  
 
If these three pharmaceuticals stay on the 
watch list and even become priority substances 
needing control, so it is likely other 
pharmaceuticals will follow. Chemotherapy 
drugs in the group known as cytostatic, 
cytotoxic, or antineoplastic (referred to 
collectively as cytostatic) are often featured on 
lists of pharmaceuticals of concern that are 
discharged into our river systems (Fent et al., 
2006; Sanderson et al., 2004), due to their 
possess fetotoxic, genotoxic and teratogenic 
properties, which have already been shown in 
fish (Grisolia, 2002) and invertebrates 
(Anderson et al., 1995). 
 
Given their societal health benefits, it is unlikely 
and perhaps undesirable for particular  
pharmaceuticals to be phased out on the basis 
of environmental concerns. Thus, as source 
controls are inappropriate, so end of pipe 
solutions may have to be sought. Geographic-
based water quality models are a practical tool 
that can address the question of exposure to 
pharmaceuticals at a continental scale. 
Measuring all of these chemicals throughout 
every European river would be exceedingly 
costly and time consuming, to say nothing of 
the problems of consistency and technical 
feasibility. 
 
Here, the results of two separate but related 
studies are presented, in which we attempted 
to predict the range of possible concentrations 
of pharmaceuticals in surface waters for 
various countries in the European Union. 
Based on publically available consumption 
data, literature data on human excretion 
values, and sewage removal rates, we predict 
concentrations of four cytostatics (i.e., 
cyclophosphamide; CP, carboplatin, 5-
fluorouracil; 5FU, and capecitabine, as well as 
the three “WFD-compounds” E2, EE2, and, 
using the geographic-based Global Water 
Availability model (GWAVA; Dumont et al., 
2012). For the latter three compounds, we 
examined whether and where predicted river 
concentrations would exceed proposed EQS 
levels of 0.4 ng/L for E2, 0.035 ng/L for EE2 
and 100 ng/L across Europe. 
 
Method 
Estimation of effluent concentrations 
The approach to estimating sewage effluent 
concentrations takes the drug consumption per 
capita for a specific country, less that 
prevented from being excreted as the free 
parent compound, and less that removed in 
sewage treatment. The effluent concentration 
is then calculated by dividing this figure by the 
per capita wastewater discharge for that nation 
(Equation 1). 
 
𝑊 =
(𝐶−𝐸−𝑆)
𝐷
 (1) 
 
Where C is consumption of the drug 
(ng/cap/d); E is the amount of the drug that is 
not excreted (ng/cap/d); S is the amount of the 
drug that is prevented from escaping into 
sewage effluent (ng/cap/d); D is the diluting 
volume of wastewater (L/cap/d); and W is the 
effluent concentration (ng/L). 
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The river concentration at the point of the 
effluent discharge (Rm, ng/L) is calculated by 
mass balance, and loss of the compound due 
to aquatic processes such as sedimentation 
and transformation is accounted for with a first 
order dissipation process to give the 
downstream concentration (Rd, ng/L) (Equation 
2). 
 
𝑅𝑑 = 𝑅𝑚 ∙ 𝑒
−𝑘∙𝑖
  (2) 
 
Where k is the decay rate (days-1) and t is the 
time of travel (days). The time of travel is the 
river reach volume divided by the flow rate 
(Dumont et al., 2012). 
 
Assessing consumption, excretion and 
sewage removal 
The most critical part of any predictive model to 
assess concentrations of human derived 
chemicals in water is obtaining information on 
usage. Fortunately, some national annual 
consumption data on cytostatic drugs are 
publically available. These were interrogated to 
assess a per capita consumption value, given 
the population of the country at a particular 
time. 
 
Next, the extent to which the parent compound 
is excreted unchanged by the patient has to be 
considered. Not surprisingly, humans vary in 
their excretion behaviour, with such factors as 
age, health, and co-medication all influencing 
the percentage excreted. This especially holds 
for the cytostatic compounds assessed. We 
therefore surveyed a wide range of literature 
on excretion rates before arriving at a mean 
value. Similarly to excretion rates, natural 
variations in sewage performance can 
influence pharmaceutical removal rates in 
treatment. Moreover, the literature on removal 
in sewage treatment for many (cytostatic) 
pharmaceuticals is still limited. 
 
European river water modelling 
To examine potential concentrations of the 
pharmaceuticals throughout European surface 
waters, the geographic-based water resources 
model GWAVA was used (Dumont et al., 
2012). This model uses geographic data on the 
location and size of the human European 
population and their association with sewage 
treatment plants (STPs) (EEA, 2011). The 
flows through these STPs are incorporated 
with the natural river discharge adjusted for 
abstractions (principally for potable supply and 
agriculture). The hydrology is driven by 
monthly climate over the period 1970-2000. 
The model calculates the water concentrations 
of chemicals through water courses in a series 
of 177,470 grid squares (cells) of 
approximately 6 x 9 km. On a monthly basis, in 
the water courses in each cell receiving 
effluent, the concentration is calculated by 
diluting the mass of chemical discharged in the 
volume of water in the cell, accounting for any 
loads from upstream cells. The chemicals are 
transported downstream with the discharge to 
the next cell. Chemical can be lost through 
abstraction or a first-order dissipation process 
(Equation 2). The time of travel through the 
gridded network (which can comprise rivers, 
lakes and wetlands) is calculated from the river 
flow rate and the water volume of each cell. 
Surface water volumes are estimated using 
established empirical relationships with width 
and depth data (Dumont et al., 2012).  
 
Results 
The GWAVA model provides predictions for 
1.2 million km of European rivers receiving the 
waste from 602.8 million people. As such, a 
single run of the model with its 177 000 grid 
squares and 31 years of climate data 
generates 66 million results per chemical. All of 
the variables discussed will play a role. 
However, the most important factor in correctly 
predicting river concentrations, apart from 
consumption, is dilution. Different 
interpretations on human excretion, or sewage 
removal rates, could change the values by up 
to 20-fold, but dilution could change the values 
by up to 1000-fold.  
 
Predictions for the four cytostatics 
The results from model runs are displayed in a 
map showing the 50th percentile concentrations 
across Europe for CP based on a mean 
excretion rate and mean sewage treatment 
removal (Fig. 1). This is broadly equivalent to 
the concentration that would be recorded at a 
median flow for that part of a river and, as 
such, might represent the typical exposure for 
surface waters. When potential worst-case 
river concentrations are modelled, such as 
might be associated with low summer flows, 
the simulations indicate that 99% of European 
river locations would be below 0.2 ng/L for 
carboplatin and below 0.6 ng/L for 5FU. With 
CP, only 0.1% of locations could exceed 1 
ng/L, whereas for capecitabine, 2.2% could 
exceed 1 ng/L in rivers.  
 
Predicted exceedances of proposed  
European EQS values for EE2, E2 and 
diclofenac 
Before starting the water quality modelling, 
based on the European mean consumption 
values, excretion values and sewage removal 
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factors, then 1 ng/L EE2, 3 ng/L E2, and 570 
ng/L diclofenac would be expected in 
European sewage effluents. At mean excretion 
and mean sewage removal, rivers where an 
annual average concentration of EE2 would 
exceed 0.035 ng/L would be fairly widespread 
with the expected scenario (Fig. 2). Of perhaps 
greater biological significance is where EE2 
concentrations might exceed 0.35 ng/L 
(Caldwell et al., 2008), and this is far less 
widespread but not negligible (Fig. 2). When all 
the results are plotted as cumulative frequency 
distributions and compared with the proposed 
EQS values, it can be seen that EE2 would 
pose the greatest challenge (Fig. 3). Between 
2 and 25% by length of Europe’s rivers were 
predicted to have EE2 concentrations in 
excess of 0.035 ng/L (best and worst case) 
with the expected outcome being 12% (Fig. 4). 
 
 
Figure 1. Predicted cyclophosphamide (CP) concentrations in surface water based on mean excretion rate, mean sewage 
treatment removal, and 50th percentile flow across the European continent, taking into account differing national per capita 
consumption and wastewater discharge values from the Global Water Availability model (GWAVA). 
 
Figure 2. Location of European surface waters where EE2 concentrations are predicted to exceed 0.035 ng/L (yellow) and 0.35 
ng/L (red) based on expected chemical discharge (mean excretion and mean sewage removal). 
 
 Book of abstracts NCR-days 2015 
 
52 
 
Figure 3. Predicted average river water concentrations throughout the European river network based on expected chemical 
discharge (mean excretion and mean sewage removal) and their proximity to the proposed EQS values in COM(2011)876. 
 
Conclusion 
Concentrations predicted for cytostatics 
We found a surprising difference in the 
popularity of the four cytostatics drugs across 
European nations, with differences of up to 28-
fold. The predicted mean effluent 
concentrations ranged from 2 ng/L to 40 ng/L 
for CP, from 0.8 ng/L to 2.5 ng/L for 
carboplatin, from 0.3 ng/L to 2.5 ng/L for 5FU, 
and from 8.5 ng/L to 87 ng/L for capecitabine. 
In the majority of cases, where data are 
available, it is possible to predict CP 
concentrations in sewage effluent to within an 
order of magnitude of that observed (data not 
shown here). By linking with the geographic-
based water quality model, it is expected that 
the majority of European rivers would have 
concentrations below 1 ng/L for these 
cytostatics drugs. 
 
Comparison with proposed EQS values and 
implications 
Given the enormous difficulties in measuring 
pictogram concentrations of E2 and EE2 in 
rivers, currently our best hope in assessing 
exposures throughout Europe is through 
modelling. With its global scope, models like 
GWAVA can be applied to continents, such as 
Europe, to assess possible river concentrations 
of pollutants originating from the human 
population. Despite limitations with respect to 
the resolution (6 x 9 km grid cells) and limited 
national consumption data for some countries 
(for which a European mean had to be 
applied), the clear message from this modelling 
exercise was that over 10% of continental 
Europe’s rivers would exceed the proposed 
EQS for EE2 of 0.035 ng/L. If such an EQS 
were to be applied across Europe, it would 
represent an enormous technical and financial 
challenge to meet, given the extent of likely 
failure predicted here. 
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